Stock Details
AMGN is Amgen Inc.'s stock. Stock exchange NasdaqGS (Currency USD). Average price in 50 days is 266.27$. Average daily volumn in 3 months 2.65M. Market cap 128.27B



Stock symbol : AMGN. Exchange : NasdaqGS. Currency : USD
Lastest price : 240.20$. Total volume : 2.76M. Market state POSTPOST
Click reload if you want to check the lastest price on market!!!

Amgen Inc. (AMGN)
Last Price
240.20$
Change
-3.80
Volume
2.76M

Previous Close244.00
Open242.99
Day Range239.60-243.56
Bid240.00 x 800
Ask240.33 x 1.2k
Volume2.76M
Average Volume2.65M
Market Cap128.27B
Beta0.63
52 Week Range214.39-296.67
Trailing P/E19.83
Foward P/E12.77
Dividend (Yield %)3.49%
Ex-Dividend Date2023-02-14



Financial Details


According to Amgen Inc.'s financial reports the company's revenue in 2022 were 26.32B an increase( +4%) over the years 2021 revenue that were of 25.98B. In 2022 the company's total earnings were 6.55B while total earnings in 2021 were 5.89B( +20%).


Loading ...



Organization

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-rel... ated events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behรงet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Market Cap:
128.27B
Revenue:
26.32B
Total Assets:
65.12B
Total Cash:
7.63B


News about "Amgen Inc."

amgen-inc-nasdaqamgn-q4-2022-earnings-call-transcript-image

Amgen Inc. (NASDAQ:AMGN) Q4 2022 Earnings Call Transcript

Source from : YAHOO!Finance - 22 hours ago

Q4 2022 Earnings Call January 31, 2023 Amgen Inc. misses on earnings expectations. Reported EPS is $4.09 EPS, expectations were $4.1. Operator: My name is Jason and I will be the conference ...See details»


amgens-q4-tops-views-but-2023-guidance-falls-on-lower-end-of-expectations-image

Amgenโ€™s Q4 tops views, but 2023 guidance falls on lower end of expectations

Source from : MarketWatch on MSN - 7 days ago

Amgen Inc. topped Wall Street expectations for its fourth quarter, but the drug maker's shares fell after hours as its 2023 guidance fell on the lower end of Wall Street's expectations.See details»


amgen-inc-stock-rises-tuesday-still-underperforms-market-image

Amgen Inc. stock rises Tuesday, still underperforms market

Source from : MarketWatch - 8 days ago

Shares of Amgen Inc. inched 0.32% higher to $252.40 Tuesday, on what proved to be an all-around positive trading session for the stock market, with the ...See details»


Amgen Inc.: Maintaining BUY following 4Q results

Source from : YAHOO!Finance - 2 days ago

Find the latest Amgen Inc. (AMGN) stock forecast based on top analyst's estimates, plus more investing and trading data from Yahoo Finance ...See details»


amgen inc.

Source from : Fox Business - 2 days ago

President Biden is set to lay out his vision Thursday for reducing the high cost of prescription drugs, and is expected to push Congress to pass legislation that would allow Medicare to negotiate ...See details»


Amgen Inc. (AMGN) May Have A Gold Mine.

Source from : stocksregister - 6 days ago

Amgen Inc. (NASDAQ:AMGN) price on Thursday, February 02, fall -2.82% below its previous dayโ€™s close as a downside momentum from buyers pushed the stockโ€™s value to $239.46. A look at the stockโ€™s price ...See details»


Amgen revenue falls slightly as Lilly COVID deal contributes less

Source from : Reuters - 8 days ago

REUTERS/Robert Galbraith/File Photo Jan 31 (Reuters) - Amgen Inc (AMGN.O) on Tuesday said its fourth-quarter revenue fell slightly as a 4% increase in sales of its own drugs was offset by lower ...See details»


Amgen Set the Record for the Biggest Biotech Acquisition Offer in 2022. Here's What Our Tools Say About the Stock

Source from : Nasdaq - 27 days ago

In mid-December, Amgen Inc. (AMGN) announced it would spend $27.8 billion to acquire Horizon Therapeutics (HZNP), paying $116.50 per share. The deal will expand Amgenโ€™s array of drugs for rare ...See details»


Amgen (AMGN) to Report Q4 Earnings: What's in the Cards?

Source from : Nasdaq - 14 days ago

Amgen, Inc. AMGN will report fourth-quarter and full-year 2022 results on Jan 31, after market close. In the last reported quarter, the company delivered an earnings surprise of 6.09%. This large ...See details»


Amgen Inc. Bottom Line Declines In Q4

Source from : Business Insider - 8 days ago

(RTTNews) - Amgen Inc. (AMGN) revealed a profit for fourth quarter that decreased from last year The company's bottom line came in at $1.62 billion, or $3.00 per share. This compares with $1.90 ...See details»


Amgen Inc.'s (NASDAQ:AMGN) institutional investors lost 3.1% over the past week but have profited from longer-term gains

Source from : Yahoo News - 8 days ago

Every investor in Amgen Inc. (NASDAQ:AMGN) should be aware of the most powerful shareholder groups. With 80% stake, institutions possess the maximum shares in the company. Put another way, the group ...See details»


Amgen launches biosimilar version of AbbVie's Humira

Source from : Yahoo News - 9 days ago

(Reuters) -Amgen Inc said on Tuesday it launched a biosimilar version of AbbVie Inc's big selling arthritis treatment, the first such competition for Humira in the United States. Amgen said its drug, ...See details»


Amgen: Q4 Earnings Snapshot

Source from : Raleigh News & Observer - 7 days ago

Amgen Inc. (AMGN) on Tuesday reported fourth-quarter earnings of $1.62 billion. On a per-share basis, the Thousand Oaks, California-based company said it had profit of $3. Earnings, adjusted for ...See details»


Amgen Shares Slip 4.1% Following Decline in 4Q Profit, Revenue

Source from : Morningstar%2c Inc. - 7 days ago

Amgen Inc. shares slipped 4.1% to $242.17 following lower profit and a dip in revenue in its latest quarter. The biotechnology company on Tuesday reported net income of $1.62 billion, or $3 a ...See details»